Cargando…
Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer
BACKGROUND: The prognostic significance of tumour budding (TB) and minimal cell nest size (MCNS) was shown in human papillomavirus (HPV)-negative head and neck squamous cell carcinomas (HNSCC). However, the optimisation of cutpoints, the prognostic impact in HPV-positive HNSCC, and the comparison wi...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241901/ https://www.ncbi.nlm.nih.gov/pubmed/37045906 http://dx.doi.org/10.1038/s41416-023-02240-y |
_version_ | 1785054093478199296 |
---|---|
author | Stögbauer, Fabian Beck, Susanne Ourailidis, Iordanis Hess, Jochen Poremba, Christopher Lauterbach, Maren Wollenberg, Barbara Buchberger, Anna Maria Stefanie Jesinghaus, Moritz Schirmacher, Peter Stenzinger, Albrecht Weichert, Wilko Boxberg, Melanie Budczies, Jan |
author_facet | Stögbauer, Fabian Beck, Susanne Ourailidis, Iordanis Hess, Jochen Poremba, Christopher Lauterbach, Maren Wollenberg, Barbara Buchberger, Anna Maria Stefanie Jesinghaus, Moritz Schirmacher, Peter Stenzinger, Albrecht Weichert, Wilko Boxberg, Melanie Budczies, Jan |
author_sort | Stögbauer, Fabian |
collection | PubMed |
description | BACKGROUND: The prognostic significance of tumour budding (TB) and minimal cell nest size (MCNS) was shown in human papillomavirus (HPV)-negative head and neck squamous cell carcinomas (HNSCC). However, the optimisation of cutpoints, the prognostic impact in HPV-positive HNSCC, and the comparison with other histopathological grading systems are insufficiently investigated. METHODS: TB and MCNS were analysed digitally in 1 and 10 high-power fields (HPF) of 331 HPV-positive and HPV-negative cases from TCGA. Optimising the cutpoints a new cellular dissociation grading (CDG) system was defined and compared to the WHO grading and the Brandwein–Gensler (BG) risk model. RESULTS: The two-tiered CDG system based solely on TB yielded optimal prognostic stratification with shortened overall survival for CDG-high cases. Optimal cut-offs were two buds (1 HPF) and six buds (10 HPF), respectively. Analysing MCNS did not add prognostic significance to quantifying TB. CDG was a significant prognostic marker in HPV-negative and HPV-positive tumours and prognostically superior to the WHO and BG systems. High CDG was associated with clinically occult lymph-node metastases. CONCLUSIONS: The most comprehensive study of TB in HNSCC so far confirmed its prognostic impact in HPV-negative tumours and for the first time in HPV-positive tumours. Further studies are warranted to evaluate its applicability for therapy guidance in HNSCC. |
format | Online Article Text |
id | pubmed-10241901 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-102419012023-06-07 Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer Stögbauer, Fabian Beck, Susanne Ourailidis, Iordanis Hess, Jochen Poremba, Christopher Lauterbach, Maren Wollenberg, Barbara Buchberger, Anna Maria Stefanie Jesinghaus, Moritz Schirmacher, Peter Stenzinger, Albrecht Weichert, Wilko Boxberg, Melanie Budczies, Jan Br J Cancer Article BACKGROUND: The prognostic significance of tumour budding (TB) and minimal cell nest size (MCNS) was shown in human papillomavirus (HPV)-negative head and neck squamous cell carcinomas (HNSCC). However, the optimisation of cutpoints, the prognostic impact in HPV-positive HNSCC, and the comparison with other histopathological grading systems are insufficiently investigated. METHODS: TB and MCNS were analysed digitally in 1 and 10 high-power fields (HPF) of 331 HPV-positive and HPV-negative cases from TCGA. Optimising the cutpoints a new cellular dissociation grading (CDG) system was defined and compared to the WHO grading and the Brandwein–Gensler (BG) risk model. RESULTS: The two-tiered CDG system based solely on TB yielded optimal prognostic stratification with shortened overall survival for CDG-high cases. Optimal cut-offs were two buds (1 HPF) and six buds (10 HPF), respectively. Analysing MCNS did not add prognostic significance to quantifying TB. CDG was a significant prognostic marker in HPV-negative and HPV-positive tumours and prognostically superior to the WHO and BG systems. High CDG was associated with clinically occult lymph-node metastases. CONCLUSIONS: The most comprehensive study of TB in HNSCC so far confirmed its prognostic impact in HPV-negative tumours and for the first time in HPV-positive tumours. Further studies are warranted to evaluate its applicability for therapy guidance in HNSCC. Nature Publishing Group UK 2023-04-12 2023-06-29 /pmc/articles/PMC10241901/ /pubmed/37045906 http://dx.doi.org/10.1038/s41416-023-02240-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Stögbauer, Fabian Beck, Susanne Ourailidis, Iordanis Hess, Jochen Poremba, Christopher Lauterbach, Maren Wollenberg, Barbara Buchberger, Anna Maria Stefanie Jesinghaus, Moritz Schirmacher, Peter Stenzinger, Albrecht Weichert, Wilko Boxberg, Melanie Budczies, Jan Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer |
title | Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer |
title_full | Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer |
title_fullStr | Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer |
title_full_unstemmed | Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer |
title_short | Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer |
title_sort | tumour budding-based grading as independent prognostic biomarker in hpv-positive and hpv-negative head and neck cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241901/ https://www.ncbi.nlm.nih.gov/pubmed/37045906 http://dx.doi.org/10.1038/s41416-023-02240-y |
work_keys_str_mv | AT stogbauerfabian tumourbuddingbasedgradingasindependentprognosticbiomarkerinhpvpositiveandhpvnegativeheadandneckcancer AT becksusanne tumourbuddingbasedgradingasindependentprognosticbiomarkerinhpvpositiveandhpvnegativeheadandneckcancer AT ourailidisiordanis tumourbuddingbasedgradingasindependentprognosticbiomarkerinhpvpositiveandhpvnegativeheadandneckcancer AT hessjochen tumourbuddingbasedgradingasindependentprognosticbiomarkerinhpvpositiveandhpvnegativeheadandneckcancer AT porembachristopher tumourbuddingbasedgradingasindependentprognosticbiomarkerinhpvpositiveandhpvnegativeheadandneckcancer AT lauterbachmaren tumourbuddingbasedgradingasindependentprognosticbiomarkerinhpvpositiveandhpvnegativeheadandneckcancer AT wollenbergbarbara tumourbuddingbasedgradingasindependentprognosticbiomarkerinhpvpositiveandhpvnegativeheadandneckcancer AT buchbergerannamariastefanie tumourbuddingbasedgradingasindependentprognosticbiomarkerinhpvpositiveandhpvnegativeheadandneckcancer AT jesinghausmoritz tumourbuddingbasedgradingasindependentprognosticbiomarkerinhpvpositiveandhpvnegativeheadandneckcancer AT schirmacherpeter tumourbuddingbasedgradingasindependentprognosticbiomarkerinhpvpositiveandhpvnegativeheadandneckcancer AT stenzingeralbrecht tumourbuddingbasedgradingasindependentprognosticbiomarkerinhpvpositiveandhpvnegativeheadandneckcancer AT weichertwilko tumourbuddingbasedgradingasindependentprognosticbiomarkerinhpvpositiveandhpvnegativeheadandneckcancer AT boxbergmelanie tumourbuddingbasedgradingasindependentprognosticbiomarkerinhpvpositiveandhpvnegativeheadandneckcancer AT budcziesjan tumourbuddingbasedgradingasindependentprognosticbiomarkerinhpvpositiveandhpvnegativeheadandneckcancer |